Guillain-Barré syndrome pathophysiology: Difference between revisions

Jump to navigation Jump to search
Line 10: Line 10:
* GBS is often associated with an antecedent infection with agents such as [[Campylobacter jejuni]] or exposure to some vacines.
* GBS is often associated with an antecedent infection with agents such as [[Campylobacter jejuni]] or exposure to some vacines.


* These causative agents have certain lipopolysaccharides antigens in their capsules that are similar to peripheral nerve [[gangliosides]] and  glycolipids, such as GM1 and GD1b.
* These causative agents have certain [[lipopolysaccharides]] [[antigens]] in their capsules that are similar to [[gangliosides]] and  [[glycolipids]], such as GM1 and GD1b found in [[myelin]] tissue of the [[peripheral nerve]].


* The immune responses directed against these bacterial capsular lipopolysaccharides also attacks the similar GM1 ganglioside in myelin of peripheral nerve.
* The immune responses directed against these bacterial capsular lipopolysaccharides also attacks the similar GM1 ganglioside in myelin of peripheral nerve.

Revision as of 13:55, 19 February 2012

Guillain-Barré syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Guillain-Barré syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Guillain-Barré syndrome pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Guillain-Barré syndrome pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Guillain-Barré syndrome pathophysiology

CDC on Guillain-Barré syndrome pathophysiology

Guillain-Barré syndrome pathophysiology in the news

Blogs on Guillain-Barré syndrome pathophysiology

Directions to Hospitals Treating Guillain-Barré syndrome

Risk calculators and risk factors for Guillain-Barré syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Priyamvada Singh, MBBS [2]

Overview

Guillain-Barré syndrome (GBS) is an acute, autoimmune, polyradiculoneuropathy affecting the peripheral nervous system, usually triggered by an acute infectious process. It is included in the wider group of peripheral neuropathies. There are several types of GBS, but unless otherwise stated, GBS refers to the most common form, acute inflammatory demyelinating polyneuropathy (AIDP). It is frequently severe and usually exhibits as an ascending paralysis noted by weakness in the legs that spreads to the upper limbs and the face along with complete loss of deep tendon reflexes. With prompt treatment of plasmapheresis followed by immunoglobulins and supportive care, the majority of patients will regain full functional capacity. However, death may occur if severe pulmonary complications and dysautonomia are present.

Pathophysiology

  • GBS is often associated with an antecedent infection with agents such as Campylobacter jejuni or exposure to some vacines.
  • The immune responses directed against these bacterial capsular lipopolysaccharides also attacks the similar GM1 ganglioside in myelin of peripheral nerve.
  • The targets of such immune attack are thought to be gangliosides, which are complex glycosphingolipids present in large quantities on human nerve tissues, especially in the nodes of Ranvier. An example is the GM1 ganglioside, which can be affected in as many as 20-50% of cases, especially in those preceded by Campylobacter jejuni infections. Another example is the GQ1b ganglioside, which is the target in the Miller Fisher syndrome variant
  • All forms of Guillain-Barré syndrome are due to an immune response to foreign antigens (such as infectious agents or vaccines) but mis-targeted to host nerve tissues instead (a form of antigenic mimicry) or molecular mimicry.
  • Cellular and humoral immune mechanisms probably play a role in its development. Pathologic findings in GBS include lymphocytic infiltration of spinal roots and peripheral nerves (cranial nerves may be involved as well), followed by macrophage-mediated, multifocal stripping of myelin.
  • The end result of such autoimmune attack on the peripheral nerves is inflammation of myelin and conduction block, leading to a muscle paralysis that may be accompanied by sensory or autonomic disturbances.
  • However, in mild cases, axonal function remains intact and recovery can be rapid if remyelination occurs.
  • In severe cases, such as in the AMAN or AMSAN variants, axonal degeneration occurs, and recovery depends on axonal regeneration.
  • Recovery becomes much slower, and there is a greater degree of residual damage. Recent studies on the disease have demonstrated that approximately 80% of the patients have myelin loss, whereas, in the remaining 20%, the pathologic hallmark of the disease is indeed axon loss.
  • Loss of myelin and axons result in defects in the propagation of electrical nerve impulses, with eventual absence or profound delay in conduction, causing flaccid paralysis.

References

Template:WH Template:WS